These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31455678)

  • 1. Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma.
    Zhou J; Sanchez-Vega F; Caso R; Tan KS; Brandt WS; Jones GD; Yan S; Adusumilli PS; Bott M; Huang J; Isbell JM; Sihag S; Molena D; Rusch VW; Chatila WK; Rekhtman N; Yang F; Ladanyi M; Solit DB; Berger MF; Schultz N; Jones DR
    Clin Cancer Res; 2019 Dec; 25(24):7475-7484. PubMed ID: 31455678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE
    Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Jones GD; Caso R; Tan KS; Mastrogiacomo B; Sanchez-Vega F; Liu Y; Connolly JG; Murciano-Goroff YR; Bott MJ; Adusumilli PS; Molena D; Rocco G; Rusch VW; Sihag S; Misale S; Yaeger R; Drilon A; Arbour KC; Riely GJ; Rosen N; Lito P; Zhang H; Lyden DC; Rudin CM; Jones DR; Li BT; Isbell JM
    Clin Cancer Res; 2021 May; 27(9):2604-2612. PubMed ID: 33593884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma.
    Lee JS; Kim EK; Kim KA; Shim HS
    Cancer Res Treat; 2024 Jan; 56(1):104-114. PubMed ID: 37499696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.
    Jones GD; Brandt WS; Shen R; Sanchez-Vega F; Tan KS; Martin A; Zhou J; Berger M; Solit DB; Schultz N; Rizvi H; Liu Y; Adamski A; Chaft JE; Riely GJ; Rocco G; Bott MJ; Molena D; Ladanyi M; Travis WD; Rekhtman N; Park BJ; Adusumilli PS; Lyden D; Imielinski M; Mayo MW; Li BT; Jones DR
    JAMA Surg; 2021 Feb; 156(2):e205601. PubMed ID: 33355651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach.
    Chang JC; Alex D; Bott M; Tan KS; Seshan V; Golden A; Sauter JL; Buonocore DJ; Vanderbilt CM; Gupta S; Desmeules P; Bodd FM; Riely GJ; Rusch VW; Jones DR; Arcila ME; Travis WD; Ladanyi M; Rekhtman N
    Clin Cancer Res; 2019 Dec; 25(23):7113-7125. PubMed ID: 31471310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
    J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations.
    Geng H; Li S; Guo Y; Yan F; Han Y; Xu M; Cui Y
    Cancer Biomark; 2020; 27(4):525-532. PubMed ID: 32083571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
    Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation sequencing in lung cancer: An initial experience from India.
    Gupta P; Saha K; Vinarkar S; Banerjee S; Choudhury SS; Parihar M; Midha D; Mukherjee G; Lingegowda D; Chatterjee S; ArunsinghS M; Shrimali R; Ganguly S; Dabkara D; Biswas B; Mishra DK; Arora N
    Curr Probl Cancer; 2020 Jun; 44(3):100562. PubMed ID: 32178863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
    Chun YJ; Choi JW; Hong MH; Jung D; Son H; Cho EK; Min YJ; Kim SW; Park K; Lee SS; Kim S; Kim HR; Cho BC;
    PLoS One; 2019; 14(11):e0224379. PubMed ID: 31765373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.
    Luo W; Tian P; Wang Y; Xu H; Chen L; Tang C; Shu Y; Zhang S; Wang Z; Zhang J; Zhang L; Jiang L; Liu L; Che G; Guo C; Zhang H; Wang J; Li W
    Int J Cancer; 2018 Oct; 143(7):1696-1705. PubMed ID: 29667179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.
    Jurmeister P; Vollbrecht C; Behnke A; Frost N; Arnold A; Treue D; Rückert JC; Neudecker J; Schweizer L; Klauschen F; Horst D; Hummel M; Dietel M; von Laffert M
    Lung Cancer; 2019 Dec; 138():43-51. PubMed ID: 31634654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
    Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
    J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinctive targetable genotypes of younger patients with lung adenocarcinoma: a cBioPortal for cancer genomics data base analysis.
    Hou H; Zhang C; Qi X; Zhou L; Liu D; Lv H; Li T; Sun D; Zhang X
    Cancer Biol Ther; 2020; 21(1):26-33. PubMed ID: 31594446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.
    Tlemsani C; Pécuchet N; Gruber A; Laurendeau I; Danel C; Riquet M; Le Pimpec-Barthes F; Fabre E; Mansuet-Lupo A; Damotte D; Alifano M; Luscan A; Rousseau B; Vidaud D; Varin J; Parfait B; Bieche I; Leroy K; Laurent-Puig P; Terris B; Blons H; Vidaud M; Pasmant E
    Cancer Med; 2019 Aug; 8(9):4330-4337. PubMed ID: 31199580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.
    Bucciarelli PR; Tan KS; Chudgar NP; Brandt W; Montecalvo J; Eguchi T; Liu Y; Aly R; Travis WD; Adusumilli PS; Jones DR
    J Thorac Oncol; 2018 Jan; 13(1):73-84. PubMed ID: 29097253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma.
    Yang SR; Lin CY; Stehr H; Long SR; Kong CS; Berry GJ; Zehnder JL; Kunder CA
    J Mol Diagn; 2018 Mar; 20(2):184-194. PubMed ID: 29269277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymph node metastasis in early invasive lung adenocarcinoma: Prediction model establishment and validation based on genomic profiling and clinicopathologic characteristics.
    Guo W; Lu T; Song Y; Li A; Feng X; Han D; Cao Y; Sun D; Gong X; Li C; Jin R; Du H; Chen K; Xiang J; Hang J; Chen G; Li H
    Cancer Med; 2024 Jul; 13(14):e70039. PubMed ID: 39046176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.